mitomycin and Thrombopenia studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Research Excerpts

Excerpt	Relevance	Reference
"The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors."	9.16	Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012)
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial."	9.14	Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."	9.10	Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs."	9.09	A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999)
" The aim of the present study was to evaluate the effectiveness and safety of a combined-treatment modality consisting of systemic chemotherapy with 24-h continuous infusional gemcitabine and mitomycin C, plus external beam radiotherapy in patients with localized unresectable adenocarcinoma of the pancreas."	9.09	Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. ( Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H, 2001)
"We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy."	9.08	Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998)
"One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i."	9.07	Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992)
"A randomized clinical trial was performed to determine if combination therapy with doxorubicin, vincristine, and mitomycin C (DVM) was superior to doxorubicin alone in women with metastatic breast cancer for whom prior chemotherapy had failed."	9.06	Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. ( Foley, JF; Gerstner, JB; Ingle, JN; Krook, JE; Long, HJ; Mailliard, JA; Marschke, RF; McCormack, GW; Pfeifle, DM; Schaid, DJ, 1989)
"Fifty-seven patients with advanced breast cancer were treated with a combination of 5-fluorouracil and mitomycin C (FuMi)."	7.67	5-Fluorouracil and mitomycin C in advanced breast cancer. ( Aspegren, K; Landberg, T, 1986)
"In 23 cases of primary advanced breast cancer, intra-arterial infusion chemotherapy of Adriamycin (ADR) and Mitomycin C (MMC), which were injected jointly or individually, was performed and its effects and side effects were studied."	7.67	[Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin]. ( Asaishi, K; Ebata, T; Hayasaka, H; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Sato, N; Toda, K; Totsuka, M, 1985)
"Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)."	7.67	Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984)
"A thrombotic microangiopathy resembling the hemolytic uremic syndrome was diagnosed in 12 patients with adenocarcinoma, in whom the tumor was in complete or near-complete remission after treatment with mitomycin C-containing drug regimens."	7.67	Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. ( Cantrell, JE; Phillips, TM; Schein, PS, 1985)
"43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i."	7.66	Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy. ( Barduagni, A; Barduagni, M; Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1983)
"In a Phase II study, 50 patients with advanced breast cancer were treated with a combination of 5-fluorouracil (1000 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen)."	7.66	A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. ( Bjelkengren, G; Hallsten, L; Mattsson, W; von Eyben, F, 1982)
"Mitomycin C together with either vindesine or vinblastine was given to 48 patients with previously treated advanced breast cancer."	7.66	Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. ( Brooks, RJ; Garewal, HS; Jones, SE; Miller, TP, 1983)
"The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors."	5.16	Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012)
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial."	5.14	Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010)
"We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer."	5.11	Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."	5.10	Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs."	5.09	A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999)
" The aim of the present study was to evaluate the effectiveness and safety of a combined-treatment modality consisting of systemic chemotherapy with 24-h continuous infusional gemcitabine and mitomycin C, plus external beam radiotherapy in patients with localized unresectable adenocarcinoma of the pancreas."	5.09	Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. ( Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H, 2001)
"We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy."	5.08	Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998)
"A comparison of patients receiving combination chemotherapy with mitomycin C, mitozantrone and methotrexate (3M) with and without tamoxifen for treatment of primary breast cancer indicates an increased risk of anaemia (P < 0."	5.07	A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. ( Ashley, SE; Luckit, J; Montes, A; O'Brien, ME; Powles, TJ; Treleaven, J, 1993)
"One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i."	5.07	Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992)
"A randomized clinical trial was performed to determine if combination therapy with doxorubicin, vincristine, and mitomycin C (DVM) was superior to doxorubicin alone in women with metastatic breast cancer for whom prior chemotherapy had failed."	5.06	Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. ( Foley, JF; Gerstner, JB; Ingle, JN; Krook, JE; Long, HJ; Mailliard, JA; Marschke, RF; McCormack, GW; Pfeifle, DM; Schaid, DJ, 1989)
"One hundred eighty-seven patients with histologically proven advanced pancreatic adenocarcinoma were randomly assigned to therapy with 5-fluorouracil (5-FU) alone, to the Mallinson regimen (combined and sequential 5-FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C), or to combined 5-FU, doxorubicin, and cisplatin (FAP)."	5.06	A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. ( Barlow, JF; Cullinan, S; Foley, JF; Kardinal, CG; Krook, JE; Moertel, CG; Norris, BD; Schutt, AJ; Tschetter, LK; Wieand, HS, 1990)
"Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C."	3.85	Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. ( Aggarwal, S; Bazan, JG; Chang, DT; Golden, DW; Kopec, M; Lee, AY; Liauw, SL; Pelizzari, CA, 2017)
"5-(2-Pyridylsulfonyl)-2-thiazolamine (2) was effective both in mitomycin C (MMC)-induced thrombocytopenia and in an animal model of idiopathic thrombocytopenic purpura (ITP)."	3.70	Synthesis and effects of novel thiazole derivatives against thrombocytopenia. ( Manda, T; Matsuo, M; Nishigaki, F; Ogino, T; Sawada, M; Seki, N; Sudo, Y; Tsuji, K, 1998)
"21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks."	3.67	Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984)
"Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)."	3.67	Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984)
"In 23 cases of primary advanced breast cancer, intra-arterial infusion chemotherapy of Adriamycin (ADR) and Mitomycin C (MMC), which were injected jointly or individually, was performed and its effects and side effects were studied."	3.67	[Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin]. ( Asaishi, K; Ebata, T; Hayasaka, H; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Sato, N; Toda, K; Totsuka, M, 1985)
"Fifty-seven patients with advanced breast cancer were treated with a combination of 5-fluorouracil and mitomycin C (FuMi)."	3.67	5-Fluorouracil and mitomycin C in advanced breast cancer. ( Aspegren, K; Landberg, T, 1986)
"A thrombotic microangiopathy resembling the hemolytic uremic syndrome was diagnosed in 12 patients with adenocarcinoma, in whom the tumor was in complete or near-complete remission after treatment with mitomycin C-containing drug regimens."	3.67	Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. ( Cantrell, JE; Phillips, TM; Schein, PS, 1985)
"In a Phase II study, 50 patients with advanced breast cancer were treated with a combination of 5-fluorouracil (1000 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen)."	3.66	A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. ( Bjelkengren, G; Hallsten, L; Mattsson, W; von Eyben, F, 1982)
"Mitomycin C together with either vindesine or vinblastine was given to 48 patients with previously treated advanced breast cancer."	3.66	Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. ( Brooks, RJ; Garewal, HS; Jones, SE; Miller, TP, 1983)
"43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i."	3.66	Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy. ( Barduagni, A; Barduagni, M; Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1983)
"We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent."	2.82	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. ( Bekaii-Saab, T; Chen, A; Duan, W; Ji, J; Lustberg, M; Marshall, J; Rose, J; Schaaf, LJ; Shilo, K; Thurmond, J; Timmers, C; Villalona-Calero, MA; Westman, JA; Xiaobai, L; Zhao, W, 2016)
"Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use."	2.80	Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. ( Amitay, Y; Berger, R; Gabizon, AA; Golan, T; Grenader, T; La-Beck, NM; Ohana, P; Shmeeda, H; Tahover, E, 2015)
"169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)."	2.72	Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006)
" Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone."	2.69	Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. ( Alexopoulos, CG; Baumöhl, J; Berghmans, T; Florin, MC; Klastersky, J; Koumakis, G; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Schmerber, J; Sculier, JP; Thiriaux, J; Zacharias, C, 2000)
"Thrombocytopenia was the most frequently observed grade 4 toxicity in both groups (11% after FM versus 12% after GC)."	1.37	Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. ( Brunner, TB; Fietkau, R; Sauer, R, 2011)
"We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy."	1.35	Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. ( Aydogan, B; Chmura, SJ; Devisetty, K; Jani, AB; Kindler, HL; Mell, LK; Miller, RC; Mundt, AJ; Roeske, JC; Salama, JK; Schomas, DA, 2008)
"To prepare a new dosage formulation of activated carbon nanoparticles adsorbing mitomycin C (MMC-ACNP) and evaluate the beneficial effects of intraperitoneally applied MMC-ACNP as a drug delivery system for lymphatic targeting in preventing metastasis and recurrence of gastric cancer."	1.33	[Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma]. ( Qu, QL; Sun, L; Yang, LZ; Zhang, YG, 2006)
"The patient was first diagnosed with squamous cell carcinoma of the anus 1 year before admission."	1.32	Cases from the Osler Medical Service at Johns Hopkins University. ( Brown, C; Zetola-Burneo, N, 2004)
"Overall median survival was 352 days in colon cancer and 449 days in gastric cancer."	1.28	[A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer]. ( Arai, Y; Endo, T; Kido, C; Miyake, Y; Sakamoto, K, 1989)
"Thirty-three patients with advanced cervical cancer (31 squamous cancer, two adenosquamous cancer) previously untreated with cytotoxic drugs, were treated with bleomycin, 5 mg daily, for seven days and mitomycin C, 10 mg, on day 8."	1.27	Bleomycin-mitomycin C in advanced carcinoma of the cervix. A third look. ( Gullberg, B; Johnsson, JE; Mattsson, W; Sigurdsson, K; Simonsen, E; Stendahl, U; Tropé, C, 1983)
"Sixty-six patients with advanced colorectal cancer were treated with 5-fluorouracil, Mitomycin C, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea."	1.27	The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer. ( Chapman, J; Chinn, B; Demitrish, MM; Enochs, K; Garland, M; Groshko, G; Pederson, B; Rocchio, R; Vaughn, CB; Ward, D, 1986)

Timeframe	Studies, this research(%)	All Research%
pre-1990	20 (33.33)	18.7374
1990's	16 (26.67)	18.2507
2000's	16 (26.67)	29.6817
2010's	8 (13.33)	24.3611
2020's	0 (0.00)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open Phase 1B Study for Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Oxaliplatin-based Chemotherapy in Patients With Gastro-intestinal Malignancies[NCT04729205]	Phase 1	9 participants (Actual)	Interventional	2021-01-13	Terminated (stopped due to Investigational drug not available)
A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.[NCT01705002]	Phase 1	88 participants (Actual)	Interventional	2012-10-31	Completed
A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809]	Phase 2	27 participants (Anticipated)	Interventional	2023-07-15	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. Cancer medicine, 2015, Volume: 4, Issue:10 Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum	2015
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. Cancer medicine, 2015, Volume: 4, Issue:10 Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum	2015
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. Cancer medicine, 2015, Volume: 4, Issue:10 Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum	2015
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. Cancer medicine, 2015, Volume: 4, Issue:10 Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum	2015
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles;	2016
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl	2010
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncology, 2012, Volume: 83, Issue:2 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Diseas	2012
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies. Clinical oncology (Royal College of Radiologists (Great Britain)), 2003, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Fema	2003
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. British journal of cancer, 2004, Jun-01, Volume: 90, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit	2004
Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. International journal of radiation oncology, biology, physics, 2005, Jan-01, Volume: 61, Issue:1 Topics: Analysis of Variance; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Thera	2005
Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. Journal of surgical oncology, 2005, Aug-01, Volume: 91, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dexamethasone; Dose-	2005
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. Oncology, 2006, Volume: 71, Issue:5-6 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci	2006
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer. American journal of clinical oncology, 1984, Volume: 7, Issue:5 Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy	1984
A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study. European journal of cancer, 1980, Volume: Suppl 1 Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Mitomycin; Mitomycins; N	1980
Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trial. European journal of gynaecological oncology, 1994, Volume: 15, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisp	1994
A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:13 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interact	1993
Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:3 Topics: Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Leukopenia; Liver Ne	1993
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anti-cancer drugs, 1998, Volume: 9, Issue:5 Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Colorectal Neoplasms; Diarrhea; Disease Progressio	1998
Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat	1999
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. Cancer investigation, 1999, Volume: 17, Issue:8 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis	1999
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. British journal of cancer, 2000, Volume: 83, Issue:9 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S	2000
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. International journal of radiation oncology, biology, physics, 2001, Mar-01, Volume: 49, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deo	2001
Unexpected increase in the bone marrow toxicity of mitomycin C (MMC). British journal of cancer, 2001, Mar-02, Volume: 84, Issue:5 Topics: Antibiotics, Antineoplastic; Bone Marrow; Female; Humans; Leukopenia; Mitomycin; Thrombocytopenia	2001
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response R	2001
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Cancer, 2002, Feb-01, Volume: 94, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined	2002
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer, 1992, Mar-15, Volume: 69, Issue:6 Topics: Acid Phosphatase; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluo	1992
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer, 1990, May-15, Volume: 65, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Proto	1990
[Effects of prophylactic intraportal chemotherapy on liver function, blood profile and survival in patients with colo-rectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap	1989
Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. American journal of clinical oncology, 1989, Volume: 12, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female;	1989

Article	Year
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy. International journal of radiation oncology, biology, physics, 2013, Dec-01, Volume: 87, Issue:5 Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis	2013
Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. International journal of radiation oncology, biology, physics, 2017, 02-01, Volume: 97, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow;	2017
Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil. Japanese journal of clinical oncology, 2008, Volume: 38, Issue:9 Topics: Absorbable Implants; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carci	2008
The prognostic value of p53 mutation in pediatric marrow hypoplasia. Diagnostic pathology, 2011, Jun-30, Volume: 6 Topics: Adolescent; Anemia, Aplastic; Autoimmune Diseases; Bone Marrow Cells; Child; Child, Preschool; Chrom	2011
Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. Radiation oncology (London, England), 2011, Jul-27, Volume: 6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluor	2011
Cases from the Osler Medical Service at Johns Hopkins University. The American journal of medicine, 2004, Feb-01, Volume: 116, Issue:3 Topics: Anemia, Hemolytic; Antibiotics, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Hu	2004
Therapeutic effects of Lycium barbarum polysaccharide (LBP) on mitomycin C (MMC)-induced myelosuppressive mice. Journal of experimental therapeutics & oncology, 2004, Volume: 4, Issue:3 Topics: Anemia; Animals; Antibiotics, Antineoplastic; Female; Hematocrit; Injections, Intravenous; Injection	2004
[Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:4 Topics: Adenocarcinoma, Mucinous; Animals; Antibiotics, Antineoplastic; Charcoal; Drug Carriers; Drug Delive	2006
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. International journal of radiation oncology, biology, physics, 2008, Apr-01, Volume: 70, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplas	2008
Bleomycin-mitomycin C in advanced carcinoma of the cervix. A third look. Cancer, 1983, Feb-15, Volume: 51, Issue:4 Topics: Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combina	1983
New preoperative chemotherapy for bladder cancer using combination hemodialysis and direct hemoperfusion: preliminary report. The Journal of urology, 1984, Volume: 131, Issue:1 Topics: Adult; Aged; Animals; Antineoplastic Agents; Bleomycin; Combined Modality Therapy; Dogs; Doxorubicin	1984
Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. Japanese journal of clinical oncology, 1984, Volume: 14, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Br	1984
Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy. Oncology, 1983, Volume: 40, Issue:4 Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combinat	1983
Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Fema	1983
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. Oncology, 1984, Volume: 41, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu	1984
Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate. Cancer treatment reports, 1984, Volume: 68, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem	1984
A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. Cancer, 1982, Jan-15, Volume: 49, Issue:2 Topics: Adult; Aged; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Hum	1982
Effect of conagenin on thrombocytopenia induced by antitumor agents in mice. The Journal of antibiotics, 1994, Volume: 47, Issue:10 Topics: Animals; Antineoplastic Agents; Bone Marrow; Cells, Cultured; Fluorouracil; Interleukin-2; Interleuk	1994
Improvement of mitomycin C- and cyclophosphamide-induced thrombocytopenia and leucocytopenia by prior treatment with deoxyspergualin in dogs. British journal of haematology, 1994, Volume: 87, Issue:3 Topics: Animals; Cyclophosphamide; Dogs; Guanidines; Immunosuppressive Agents; Leukocyte Count; Leukopenia;	1994
Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice. Stem cells (Dayton, Ohio), 1996, Volume: 14, Issue:6 Topics: Animals; Disease Models, Animal; Granulocyte Colony-Stimulating Factor; Humans; Male; Mice; Mice, In	1996
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas. American journal of clinical oncology, 1997, Volume: 20, Issue:5 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An	1997
Synthesis and effects of novel thiazole derivatives against thrombocytopenia. Bioorganic & medicinal chemistry letters, 1998, Sep-22, Volume: 8, Issue:18 Topics: Animals; Autoantibodies; Blood Platelets; Dapsone; Disease Models, Animal; Dose-Response Relationshi	1998
Kinetic analysis of megakaryopoiesis induced by recombinant human interleukin 11 in myelosuppressed mice. Cytokine, 2001, Mar-07, Volume: 13, Issue:5 Topics: Alkylating Agents; Animals; Blood Platelets; Bone Marrow Cells; Cell Differentiation; Cell Division;	2001
[The relation between myelotoxicity and performance status or aging in chemotherapy of non-small cell lung cancer]. Nihon Kyobu Shikkan Gakkai zasshi, 1991, Volume: 29, Issue:2 Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino	1991
[Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small	1990
[A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Flu	1989
[Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin]. Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:12 Topics: Alopecia; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Eruptions; Female; Human	1985
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer. American journal of clinical oncology, 1986, Volume: 9, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Flu	1986
5-Fluorouracil and mitomycin C in advanced breast cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1986, Volume: 6, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil;	1986
Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma. Canadian journal of physiology and pharmacology, 1987, Volume: 65, Issue:3 Topics: Aged; Chromatography, High Pressure Liquid; Colonic Neoplasms; Half-Life; Humans; Kidney; Kinetics;	1987
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu	1988
Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:5 Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Anemia, Hemolytic; Antibiotics, Antineoplastic; Antigen-	1985
Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors. Japanese journal of clinical oncology, 1985, Volume: 15, Issue:1 Topics: Adult; Aged; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomyci	1985

mitomycin and Thrombopenia

Research Excerpts

Research

Studies (60)

Authors

Clinical Trials (3)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Bazan, JG	2
Luxton, G	1
Kozak, MM	1
Anderson, EM	1
Hancock, SL	1
Kapp, DS	1
Kidd, EA	1
Koong, AC	1
Chang, DT	2
Golan, T	1
Grenader, T	1
Ohana, P	1
Amitay, Y	1
Shmeeda, H	1
La-Beck, NM	1
Tahover, E	1
Berger, R	1
Gabizon, AA	1
Villalona-Calero, MA	1
Duan, W	1
Zhao, W	1
Shilo, K	1
Schaaf, LJ	1
Thurmond, J	1
Westman, JA	1
Marshall, J	1
Xiaobai, L	1
Ji, J	1
Rose, J	1
Lustberg, M	1
Bekaii-Saab, T	1
Chen, A	1
Timmers, C	1
Lee, AY	1
Golden, DW	1
Kopec, M	1
Pelizzari, CA	1
Aggarwal, S	1
Liauw, SL	1
Ishida, K	1
Hirooka, M	1
Hiraoka, A	1
Kumagi, T	1
Uehara, T	1
Hiasa, Y	1
Horiike, N	1
Onji, M	1
Tebbutt, NC	2
Wilson, K	1
Gebski, VJ	1
Cummins, MM	1
Zannino, D	1
van Hazel, GA	1
Robinson, B	1
Broad, A	1
Ganju, V	1
Ackland, SP	1
Forgeson, G	1
Cunningham, D	2
Saunders, MP	1
Stockler, MR	1
Chua, Y	1
Zalcberg, JR	1
Simes, RJ	1
Price, TJ	1
Abo-Elwafa, HA	1
Attia, FM	1
Sharaf, AE	1
Brunner, TB	1
Sauer, R	1
Fietkau, R	1
Lim, KH	1
Han, SW	1
Oh, DY	1
Im, SA	1
Kim, TY	1
Bang, YJ	1
Kelleher, M	1
Andreyev, J	1
Allen, M	1
Hill, M	1
Norman, A	1
Zetola-Burneo, N	1
Brown, C	1
Hussain, SA	1
Stocken, DD	1
Peake, DR	1
Glaholm, JG	1
Zarkar, A	1
Wallace, DM	1
James, ND	1
Haffty, BG	1
Wilson, LD	1
Son, YH	1
Cho, EI	1
Papac, RJ	1
Fischer, DB	1
Rockwell, S	1
Sartorelli, AC	1
Ross, DA	1
Sasaki, CT	1
Fischer, JJ	1
Hai-Yang, G	1
Ping, S	1
Li, JI	1
Chang-Hong, X	1
Fu, T	1
Kemeny, N	1
Eid, A	1
Stockman, J	1
Gonen, M	1
Schwartz, L	1
Tetzlaff, E	1
Paty, P	1
Qu, QL	1
Zhang, YG	1
Yang, LZ	1
Sun, L	1
Di Bartolomeo, M	1
Buzzoni, R	1
Mariani, L	1
Ferrario, E	1
Katia, D	1
Gevorgyan, A	1
Zilembo, N	1
Bordonaro, R	1
Bochicchio, AM	1
Massidda, B	1
Ardizzoia, A	1
Ardizzoni, A	1
Marini, G	1
Aitini, E	1
Schieppati, G	1
Comella, G	1
Pinotti, G	1
Palazzo, S	1
Cicero, G	1
Bajetta, E	1
Villa, E	1
Fagnani, D	1
Reguzzoni, G	1
Agostana, B	1
Oliani, C	1
Kildani, B	1
Duro, M	1
Botta, M	1
Mozzana, R	1
Mantovani, G	1
Mell, LK	1
Schomas, DA	1
Salama, JK	1
Devisetty, K	1
Aydogan, B	1
Miller, RC	1
Jani, AB	1
Kindler, HL	1
Mundt, AJ	1
Roeske, JC	1
Chmura, SJ	1
Tropé, C	1
Johnsson, JE	1
Simonsen, E	1
Sigurdsson, K	1
Stendahl, U	1
Mattsson, W	2
Gullberg, B	1
Kamidono, S	1
Fujii, A	1
Hamami, G	1
Nakano, Y	1
Umezu, K	1
Oda, Y	1
Ishigami, J	1
Salvati, F	1
Cruciani, AR	1
De Marinis, A	1
Nunziati, F	1
Portalone, L	1
Lopez, M	1
Papaldo, P	1
Di Lauro, L	1
Barduagni, M	1
Perno, CF	1
Barduagni, A	1
Garewal, HS	1
Brooks, RJ	1
Jones, SE	1
Miller, TP	1
DiBella, NJ	1
Garfield, D	1
Fink, K	1
Anderson, P	1
Speer, J	1
Murphy, J	1
Beck, TM	1
Curtis, PW	1
Woodard, DA	1
Hart, NE	1
Smith, CE	1
Chahinian, AP	1
Green, G	1
Holland, JF	1
von Eyben, F	1
Hallsten, L	1
Bjelkengren, G	1
van Oosterom, AT	1
Powles, TJ	2
Hamersma, E	1
Smith, IE	1
Engelsman, E	1
Hempling, RE	1
Piver, MS	1
Baker, TR	1
O'Neill Mullen, C	1
Kawatsu, M	1
Yamashita, T	1
Ishizuka, M	1
Takeuchi, T	3
Nemoto, K	1
Ogino, M	1
Sugawara, Y	1
Abe, F	1
Ito, J	1
Montes, A	1
O'Brien, ME	1
Ashley, SE	1
Luckit, J	1
Treleaven, J	1
Grau, JJ	1
Estapé, J	1
Alcobendas, F	1
Pera, C	1
Daniels, M	1
Terés, J	1
Akahori, H	1
Shibuya, K	1
Ozai, M	1
Ida, M	1
Kabaya, K	1
Kato, T	1
Miyazaki, H	2
Iop, A	1
Cartei, G	1
Vigevani, E	1
Clocchiatti, L	1
Mansutti, M	1
Sibau, AM	1
Hartmann, JT	1
Harstrick, A	1
Daikeler, T	1
Kollmannsberger, C	1
Müller, C	1
Seeber, S	1
Kanz, L	1
Bokemeyer, C	1
Tsuji, K	1
Ogino, T	1
Seki, N	1
Sawada, M	1
Sudo, Y	1
Nishigaki, F	1
Manda, T	1
Matsuo, M	1
Furuse, K	1
Kawahara, M	1
Nishiwaki, Y	1
Fukuoka, M	1
Takada, M	1
Miyashita, M	1
Ohashi, Y	1
Anderson, N	1
Lokich, J	1
Moore, C	1
Bern, M	1
Coco, F	1
Sculier, JP	1
Lafitte, JJ	1
Paesmans, M	1
Thiriaux, J	1
Alexopoulos, CG	1
Baumöhl, J	1
Schmerber, J	1
Koumakis, G	1
Florin, MC	1
Zacharias, C	1
Berghmans, T	1
Mommen, P	1
Ninane, V	1
Klastersky, J	1
Kornek, GV	1
Pötter, R	1
Selzer, E	1
Schratter, A	1
Ulrich-Pur, H	1
Rogy, M	1
Kraus, G	1
Scheithauer, W	1
Yoshimoto, M	1
Saito, M	1
Tada, T	1
Kasumi, KT	1
Saitoh, M	1
Taguchi, K	1
Momose, K	1
Suga, K	1
Ogawa, Y	1
Yasuda, S	1
Miyata, K	1
Yamao, T	1
Shirao, K	1
Matsumura, Y	1
Muro, K	1
Yamada, Y	2
Goto, M	1
Chin, K	1
Shimada, Y	1
Edmonson, JH	1
Petersen, IA	1
Shives, TC	1
Mahoney, MR	1
Rock, MG	1
Haddock, MG	1
Sim, FH	1
Maples, WJ	1
O'Connor, MI	1
Gunderson, LL	1
Foo, ML	1
Pritchard, DJ	1
Buckner, JC	1
Stafford, SL	1
Laurie, JA	1
Hahn, RG	1
Therneau, TM	1
Patel, SR	1
Mailliard, JA	2
Windschitl, HE	1
Twito, DI	1
Morton, RF	1
Krook, JE	3
Oshita, F	1
Shinkai, T	2
Miya, T	1
Kojima, A	1
Ohe, Y	1
Tamura, T	1
Sasaki, Y	2
Eguchi, K	2
Saijo, N	2
Hayashi, Y	1
Kato, M	1
Matsuura, T	1
Adachi, S	1
Ito, G	1
Yamamoto, K	1
Cullinan, S	1
Moertel, CG	1
Wieand, HS	1
Schutt, AJ	1
Foley, JF	2
Norris, BD	1
Kardinal, CG	1
Tschetter, LK	1
Barlow, JF	1
Inoue, Y	1
Sawada, T	1
Shimizu, T	1
Ishiguro, M	1
Wakatsuki, T	1
Hamazoe, R	1
Shimizu, N	1
Maeta, M	1
Koga, S	1
Ingle, JN	1
Schaid, DJ	1
Gerstner, JB	1
Pfeifle, DM	1
Marschke, RF	1
Long, HJ	1
McCormack, GW	1
Arai, Y	1
Endo, T	1
Miyake, Y	1
Sakamoto, K	1
Kido, C	1
Toda, K	1
Asaishi, K	1
Okazaki, A	1
Okazaki, Y	1
Okazaki, M	1
Ebata, T	1
Totsuka, M	1
Hayasaka, H	1
Sato, N	1
Narimatsu, E	1
Vaughn, CB	1
Chapman, J	1
Garland, M	1
Pederson, B	1
Demitrish, MM	1
Chinn, B	1
Ward, D	1
Enochs, K	1
Groshko, G	1
Rocchio, R	1
Aspegren, K	1
Landberg, T	1
Erlichman, C	1
Rauth, AM	1
Battistella, R	1
Fine, S	1
van der Gaast, A	1
Verweij, J	1
Planting, AS	1
Stoter, G	1
Cantrell, JE	1
Phillips, TM	1
Schein, PS	1
Tominaga, K	1
Shimizu, E	1
Fujita, J	1
Futami, H	1
Hoshi, A	1